

Microemboli monitoring by trans-cranial doppler in patient with acute cardioemboligenic stroke due to atrial myxoma

Gregory Telman,¹ Orit Mesica,¹
Efim Kouperberg,¹ Oved Cohen,²
Gil Bolotin,² Yoram Agmon³

¹Departments of Neurology, ²Cardiac Surgery, and ³Cardiology, Rambam Health Care Campus and Technion Faculty of Medicine, Haifa, Israel

Abstract

This is the first reported attempt to examine the emboliogenic potential of cardiac myxoma in patients with acute stroke through the monitoring of microembolic signals (MES) by transcranial doppler. A 43-year old woman was brought to the emergency department because of acute onset of generalized tonic-clonic seizures and left hemiplegia. A CT scan of the brain demonstrated a large acute infraction in the territory of the right middle cerebral artery (MCA) and another smaller one in the territory of the posterior cerebral artery on the same side. Trans-cranial doppler (TCD) microemboli monitoring did not reveal MES. Transesophageal echocardiography (TEE) identified a 5 cm left atrial mass, which was highly suspected to be an atrial myxoma attached to the interatrial septum and prolapsed through the mitral valve. After the TEE results were obtained, another TCD monitoring was performed. Again, there were no MES found in either of the MCAs.

Our findings showed the absence of MES on two consecutive TCD examinations, suggesting a spontaneous occurrence, rather than the permanent presence, of embolization, even in the most acute phase of stroke. Thus, the tendency of myxomas to spontaneously produce multiple emboli emphasizes the need for the surgical excision of myxomas.

Introduction

Left atrial myxoma is a benign primary cardiac tumor and a cause of embolic stroke. Primary tumors of the heart are rare and 75% of those tumors are benign. Nearly half of the benign heart tumors are myxomas, making it the most common heart tumor. Although classified as benign tumors, myxomas seem to grow and spread, but there is still debate as to whether they metastasize or fragments simply

embolize.¹ There is a 2:1 female preponderance and the age at onset is usually between 30-60 years. Although atrial myxoma is largely sporadic, at least 7% of cases are familial. Atrial myxomas have been estimated to cause up to 0.5% of ischemic stroke.² Stroke appears to be responsible for 80% of the neurological presentations of myxomas, and only 40% of these have a typical pattern of cardioembolism involving several vascular territories. Myxoma usually causes ischemic stroke by embolism of tumor or thrombus, but aneurismal dilations at sites of earlier embolic vascular occlusion can cause intracerebral or subarachnoid hemorrhage.³

Cerebral imaging often demonstrates multiple infarcts suggestive of an embolic cause, but in some cases it may show only small subcortical ischemic lesions, as seen in lacunar infarcts.⁴ Transthoracic echocardiography has approximately 90% sensitivity in the detection of left atrial myxoma, while the sensitivity of transesophageal examination is 100%. Transesophageal examination is also preferred because of its ability to detect other cardioembolic sources, such as intracardiac thrombus, vegetations, or aortic arch plaque.⁵ General or constitutional manifestations, such as fatigue, fever, erythematous rash, arthralgia, myalgia, and weight loss, as well as laboratory abnormalities, such as anemia and elevated ESR and serum C reactive protein and globulin levels, have been observed in many patients irrespective of the site and size of the myxoma. The risk of recurrent myxoma is 1-3% for sporadic cases, and it is usually attributed to multifocal myxoma embolization or incomplete resection. Follow-up by echocardiography is recommended.¹

It has not yet been established as to whether transcranial Doppler (TCD) can be used as a means to examine the emboliogenic potential of cardiac myxoma in patients with acute stroke.

Case Report

A 43-year old woman from the Philippines was brought to the emergency department of Rambam Medical Center in Haifa, Israel because of acute onset of generalized tonic-clonic seizures and left hemiplegia. The patient was generally healthy without any kind of treatment or risk factors. No history of previous transient neurological deficit was reported. On physical examination, she was found to be in a stupor. Her vital signs were normal, and cardiac exam revealed sinus rhythm without heart murmurs. Neurological examination showed left central facial palsy, eye deviation to the right, left hemiplegia, brisk deep tendon reflexes, and extensor plantar reflex on the

Correspondence: Gregory Telman, Dept. of Neurology, Rambam Health Care Campus, Haifa, Israel. E-mail: g_telman@rambam.health.gov.il

Key words: myxoma, stroke, transcranial doppler.

Received for publication: 8 June 2009.

Revision received: 9 December 2009.

Accepted for publication: 20 January 2010.

This work is licensed under a Creative Commons Attribution 3.0 License (by-nc 3.0).

©Copyright G. Telman et al., 2010
Licensee PAGEPress, Italy
Neurology International 2010; 2:e5
doi:10.4081/ni.2010.e5

left. A CT scan of the brain on admission revealed a small old right parietal lobe infraction. Another CT was performed 24 hours later and revealed a large acute infraction in the territory of the right middle cerebral artery (MCA) and another smaller one in the territory of the posterior cerebral artery on the same side. The erythrocyte sedimentation rate was 72 mm in the first hour with no anemia. Blood coagulation, lipid and homocysteine levels were normal. Treatment with phenytoin and plavix was started. Carotid duplex, including common, internal and external carotid arteries and vertebral arteries, was normal.

TCD (Pioneer, TC 8080, Viasys™, Nicolet) microemboli monitoring was performed for 30 minutes, with both MCAs monitored. No microembolic signals (MES) were revealed. Examination of cerebral blood flow velocities was normal. Cardiac holter showed a sinus rhythm average of 74 (62-119) without tachy or brady-arrhythmia or conduction disturbances. Transesophageal echocardiography (TEE) identified a 5 cm left atrial mass, which was highly suspected to be an atrial myxoma (Figure 1) attached to the interatrial septum and prolapsed through the mitral valve (without significant LV inflow obstruction in the supine position). After the TEE results were obtained, another TCD monitoring was performed and continued this time for one hour. Again, there were no MES found in either of the MCAs. The myxoma was resected 23 days after admission. Transthoracic echocardiography was performed three days after surgery and showed no evidence of residual myxoma or atrial septal defect. The patient was referred for further rehabilitation because of severe left hemiparesis.

Discussion

One of the widely used applications of TCD

is MES monitoring. This technique provides useful information about possible sources of embolism, as well as their activity. Acute ischemic stroke, carotid stenosis, and cardiac diseases are the most studied areas in the field of MES monitoring. The significance of MES in patients with cerebrovascular diseases has been the subject of many studies. The short Pubmed literature search by combination of MES and stroke retrieved 122 related items.

The first line of research is devoted to revealing the prevalence and timing of MES appearance in patients with acute ischemic stroke. It is now well established that MES is a frequent phenomenon in patients with ischemic stroke and that the amount of MES is related to stroke onset, with the peak occurring in the first hours and days after stroke.⁶⁻¹⁰ Many other important studies have been devoted to the key issue of using the presence and amount of MES as predictors of the short- and long-term clinical outcomes during the index event, as well as possible predictors of recurrent ischemic stroke.¹¹⁻¹⁷ Studies exploring the correlation between prevalence and amount of MES and the etiology of ischemic stroke can also be found in the literature.¹⁸⁻²³

Another line of research estimates the impact of MES in both symptomatic and asymptomatic carotid disease. In patients suffering from carotid stenosis, the presence of MES can be indicative of an unstable structure of carotid plaque that is prone to be a source of emboli. The existence of MES in patients with carotid disease is also an important indicator of the substantial danger of the first and recurrent cerebrovascular event.²⁴⁻²⁹ Another area in which the presence of MES determines the increased risk of peri- and post-procedural complications is that of carotid surgery and stenting. In both cases, the appearance of a significant amount of MES reflects damage of the plaque, resulting in multiple emboli with neurological and cognitive impairment.³⁰⁻⁴²

In cardiology, TCD is a reliable technique for the detection of MES from cardiac embolic sources, such as prosthetic cardiac valves,⁴³⁻⁴⁵ aortic plaques,^{48,46-48} and atrial fibrillation.^{20,23,49} It is also used as an especially sensitive technique for detecting right-to-left cardiac or pulmonary shunts.⁵⁰⁻⁵⁶ The microembolic signals obtained from patients with artificial heart valves and during examinations for PFO detection have also been used as a model, alongside other methods, in an attempt to differentiate between gaseous and solid microemboli.⁵⁷⁻⁵⁹ The results of MES monitoring may also be found in some other clinical situations, where their presence⁶⁰⁻⁶⁵ or absence⁶⁶⁻⁶⁷ helps us to better understand the role of embolism in the development of the disease. Our case emphasizes that MES monitoring may be useful not only in detecting the emboliogenic nature of the disease, but also in exploring the precise




Figure 1. Multiple trans-oesophageal images of a large left atrial myxoma (marked by *). Long-axis mid-oesophageal views of the heart (A – systole, B – early diastole, C – mid-diastole) demonstrating prolapse of the myxoma from the left atrium into the left ventricle during diastole. Multiple, mobile, “finger-like” projections of the tumor were evident (thin arrows). Four-chamber mid-oesophageal view (D) showing the connection of the tumor to the interatrial septum (thick arrow). LA = left atrium, LV = left ventricle, Ao = ascending aorta, AoV = aortic valve, RV = right ventricle.

timing of embolization (i.e., either permanent, as in the many clinical situations mentioned above, or sporadic, as in our case).

Although cardiac myxoma is a rare disease, it should be considered in young patients with stroke and elevated ESR, even without systemic symptoms. There are no data in the literature about TCD monitoring in patients with atrial myxomas. Our findings showed the absence of MES on two consecutive TCD examinations, suggesting a spontaneous occurrence, rather than the permanent presence, of embolization, even in the most acute phase of stroke. These data are compatible with literature sources pointing to the simultaneous appearance of multiple emboli at different target sites in patients presenting with cardiac myxomas.⁶⁸ Another line of evidence supporting our data is the large number of silent lesions commonly found in patients with stroke and myxomas,⁶⁹ as in the case of the patient presented here. Thus, it seems that in many cases, despite silent embolic events, the patient may remain clinically intact for years until a symptomatic event occurs. The tendency of myxomas to spontaneously produce severe and multiple emboli emphasizes the need for the surgical excision of myxomas when possible anticoagulation seems to be doubtful.

References

1. Reynen KN. Cardiac myxomas. *Engl J Med* 1995;333:1610-7
2. Herbst M, Wattjes MP, Urbach H, et al. Cerebral embolism from left atrial myxoma leading to cerebral and retinal aneurysms: a case report. *AJNR Am J Neuro-radiol* 2005;26:666-9.
3. Al-Shahi Salman R, Northridge D, Graham AN, Grant R. Stroke due to a cardiac myxoma. *Pract Neurol* 2007;7:52-5.
4. Kawamura T, Muratani H, Inamura T, et al. Serial MRI of cerebral infarcts before and after removal of an atrial myxoma. *Neuroradiology* 1999;41:573-5
5. Engberding R, Daniel WG, Erbel R, et al. Diagnosis of heart tumors by transoesophageal echocardiography: a multicentre study in 154 patients. *European Cooperative Study Group. Eur Heart J* 1993;14:1223-8.
6. Sliwka U, Lingnau A, Stohlmann WD, et al. Prevalence and time course of microembolic signals in patients with acute stroke. A prospective study. *Stroke* 1997;28:358-63.
7. Del Sette M, Angeli S, Stara I, et al. Microembolic signals with serial transcranial doppler monitoring in acute focal ischemic deficit: a local phenomenon? *Stroke*

- 1997;28:1311-3.
8. Kaposzta Z, Young E, Bath P, Markus H. Clinical application of asymptomatic embolic signal detection in acute stroke: a prospective study. *Stroke* 1999;30:1814-8.
 9. Segura T, Serena J, Castellanos M, et al. Embolism in acute middle cerebral artery stenosis. *Neurology* 2001;56:497-501.
 10. Poppert H, Sadikovic S, Sander K, et al. Embolic signals in selected stroke patients: prevalence and diagnostic benefit. *Stroke* 2006;37:2039-43.
 11. Iguchi Y, Kimura K, Kobayashi K, et al. Microembolic signals at 48 hours after stroke onset contribute to new ischaemia within a week. *J Neurol Neurosurg Psychiatry* 2008;79:253-9.
 12. Valton L, Larrue V, le Traon A, et al. Microembolic signals and risk of early recurrence in patients with stroke or transient ischemic attack. *Stroke* 1998;29:2125-8.
 13. Vassileva E, Schnorf H, Personeni O, Le Floch-Rohr J. Microembolic signals and early recurrent cerebral ischemia in carotid artery disease. *Stroke* 1999;30:1490-3.
 14. Goertler M, Blaser T, Krueger S, et al. Cessation of embolic signals after antithrombotic prevention is related to reduced risk of recurrent arterioembolic transient ischaemic attack and stroke. *J Neurol Neurosurg Psychiatry* 2002;72:338-42.
 15. Gao S, Wong KS, Hansberg T, et al. Microembolic signal predicts recurrent cerebral ischemic events in acute stroke patients with middle cerebral artery stenosis. *Stroke* 2004;35:2832-6.
 16. Blaser T, Glanz W, Krueger S, et al. Time period required for transcranial doppler monitoring of embolic signals to predict recurrent risk of embolic transient ischemic attack and stroke from arterial stenosis. *Stroke* 2004;35:2155-9.
 17. Iguchi Y, Kimura K, Kobayashi K, et al. Microembolic signals after 7 days but not within 24 hours of stroke onset should be predictor of stroke recurrence. *J Neurol Sci* 2007;263:54-8.
 18. Rundek T, Di Tullio MR, Sciacca R, et al. Association between large aortic arch atheromas and high-intensity transient signals in elderly stroke patients. *Stroke* 1999;30:2683-6.
 19. Molina CA, Alvarez-Sabin J, Schonewille W, et al. Cerebral microembolism in acute spontaneous internal carotid artery dissection. *Neurology* 2000;55:1738-41.
 20. Kumral E, Balkir K, Uzun N, et al. Microembolic signal detection in patients with symptomatic and asymptomatic lone atrial fibrillation. *Cerebrovasc Dis* 2001;12:192-6.
 21. Droste DW, Ritter M, Kemény V, et al. Microembolus detections at follow-up in 19 patients with acute stroke: correlation with stroke etiology and antithrombotic treatment. *Cerebrovasc Dis* 2000;10:272-7.
 22. Serena J, Segura T, Castellanos M, Dávalos A. Microembolic signal monitoring in hemispheric acute ischaemic stroke: a prospective study. *Cerebrovasc Dis* 2000;10:278-82.
 23. Georgiadis D, Lindner A, Manz M, et al. Intracranial microembolic signals in 500 patients with potential cardiac or carotid embolic source and in normal controls. *Stroke* 1997;28:1203-7.
 24. Sitzer M, Muller W, Siebler M, et al. Plaque ulceration and lumen thrombus are the main sources of cerebral microemboli in high-grade internal carotid artery stenosis. *Stroke* 1995;26:1231-3.
 25. Valton L, Larrue V, Arrue P, et al. Asymptomatic cerebral embolic signals in patients with carotid artery stenosis: correlation with appearance of plaque ulceration on angiography. *Stroke* 1995;26:813-5.
 26. Stork J, Kimura K, Levi C, et al. Source of microembolic signals in patients with high-grade carotid stenosis. *Stroke* 2002;33:2014-8.
 27. Markus H, Droste D, Kaps M, et al. Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the clopidogrel and aspirin for reduction of emboli in symptomatic carotid stenosis (CARESS) Trial. *Circulation* 2005;111:2233-40.
 28. Siebler M, Kleinschmidt A, Sitzer M, et al. Cerebral microembolism in symptomatic and asymptomatic high-grade internal carotid artery stenosis. *Neurology* 1994;44:615-8.
 29. Molloy J, Markus HS. Asymptomatic embolization predicts stroke and TIA risk in patients with carotid artery stenosis. *Stroke* 1999;30:1440-3.
 30. Siebler M, Sitzer M, Rose G, et al. Silent cerebral embolism caused by neurologically symptomatic high-grade carotid stenosis: event rates before and after carotid endarterectomy. *Brain* 1993;116:1005-15.
 31. Spencer MP. Transcranial Doppler monitoring and causes of stroke from carotid endarterectomy. *Stroke* 1997;28:685-91.
 32. Levi CR, O'Malley HM, Fell G, et al. Transcranial Doppler detected cerebral microembolism following carotid endarterectomy. High microembolic signal loads predict postoperative cerebral ischaemia. *Brain* 1997;120:621-9.
 33. Crawley F, Clifton A, Buckenham T, et al. Comparison of hemodynamic cerebral ischemia and microembolic signals detected during carotid endarterectomy and carotid angioplasty. *Stroke* 1997;28:2460-4.
 34. Cantelmo NL, Babikian VL, Samaraweera RN, et al. Cerebral microembolism and ischemic changes associated with carotid endarterectomy. *J Vasc Surg* 1998;27:1024-30.
 35. Stork JL, Levi CR, Chambers BR, et al. Possible determinants of early microembolism after carotid endarterectomy. *Stroke* 2002;33:2082-5.
 36. Wolf O, Heider P, Heinz M, et al. Microembolic signals detected by transcranial Doppler sonography during carotid endarterectomy and correlation with serial diffusion-weighted imaging. *Stroke* 2004;35:e373-5.
 37. Ogasawara K, Suga Y, Sasaki M, et al. Intraoperative microemboli and low middle cerebral artery blood flow velocity are additive in predicting development of cerebral ischemic events after carotid endarterectomy. *Stroke* 2008;39:3088-91.
 38. Censori B, Camerlingo M, Casto L, et al. Carotid stents are not a source of microemboli late after deployment. *Acta Neurol Scand* 2000;102:27-30.
 39. Al-Mubarak N, Roubin GS, Vitek JJ, et al. Effect of the distal-balloon protection system on microembolization during carotid stenting. *Circulation* 2001;104:1999-2002.
 40. Orlandi G, Fanucchi S, Gallerini S, et al. Impaired clearance of microemboli and cerebrovascular symptoms during carotid stenting procedures. *Arch Neurol* 2005;62:1208-11.
 41. Skjelland M, Krohg-Sørensen K, Tennøe B, et al. Cerebral microemboli and brain injury during carotid artery endarterectomy and stenting. *Stroke* 2009;40:230-4.
 42. Gossetti B, Gattuso R, Irace L, et al. Embolism to the brain during carotid stenting and surgery. *Acta Chir Belg* 2007;107:151-4.
 43. Georgiadis D, Preiss M, Lindner A, et al. Doppler microembolic signals in children with prosthetic cardiac valves. *Stroke* 1997;28:1328-9.
 44. Del Sette M, Angeli S, Badano L, et al. Prevalence of microembolic signals in patients with different types of mono-leaflet and bi-leaflet prosthetic heart valves. *Ital J Neurol Sci* 1998;19:311-4.
 45. Dittrich R, Ringelstein EB. Occurrence and clinical impact of microembolic signals during or after cardio-surgical procedures. *Stroke* 2008;39:503-11.
 46. Castellanos M, Serena J, Segura T, et al. Atherosclerotic aortic arch plaques in cryptogenic stroke: a microembolic signal monitoring study. *Eur Neurol* 2001;45:145-50.
 47. Schulte-Altedorneburg G, Nam EM, Ritter M, et al. On the origin of microembolic signals—a clinical and postmortem study. *J*

- Neurol 2003;250:1044-9.
48. Dittrich R, Ringelstein EB. Occurrence and clinical impact of microembolic signals (MES) in patients with chronic cardiac diseases and atheroarterial plaques—a systematic review. *Curr Vasc Pharmacol* 2008;6:329-34.
 49. Eicke BM, Barth V, Kukowski B, et al. Cardiac microembolism: prevalence and clinical outcome. *J Neurol Sci* 1996;136:143-7.
 50. Klötzsch C, Janssen G, Berlit P. Transesophageal echocardiography and contrast-TCD in the detection of a patent foramen ovale: experiences with 111 patients. *Neurology* 1994;44:1603-6.
 51. Hamann GF, Schätzer-Klotz D, Fröhlig G, et al. Femoral injection of echo contrast medium may increase the sensitivity of testing for a patent foramen ovale. *Neurology* 1998;50:1423-8.
 52. Arquizan C, Coste J, Touboul PJ, Mas JL. Is patent foramen ovale a family trait? A transcranial Doppler sonographic study. *Stroke* 2001;32:1563-6.
 53. Anzola GP, Morandi E, Casilli F, Onorato E. Does transcatheter closure of patent foramen ovale really "shut the door?" A prospective study with transcranial Doppler. *Stroke* 2004;35:2140-4.
 54. Nedeltchev K, Mattle HP. Contrast-enhanced transcranial Doppler ultrasound for diagnosis of patent foramen ovale. *Front Neurol Neurosci* 2006;21:206-15.
 55. Telman G, Kouperberg E, Sprecher E, Yarnitsky D. Countable and non-countable microembolic signals by TCD in first-ever stroke or TIA patients with PFO. *J Neurol Sci* 2008;268:83-6.
 56. Feurer R, Sadikovic S, Esposito L, et al. Lesion patterns in patients with cryptogenic stroke with and without right-to-left shunt. *Eur J Neurol*. 2009;16:1077-82.
 57. Telman G, Kouperberg E, Sprecher E, Yarnitsky D. The nature of microemboli in patients with artificial heart valves. *J Neuroimaging* 2002;12:15-8.
 58. Kaps M, Hansen J, Weiher M, et al. Clinically silent microemboli in patients with artificial prosthetic aortic valves are predominantly gaseous and not solid. *Stroke* 1997;28:322-5.
 59. Thoennissen NH, Allroggen A, Dittrich R, et al. Can Doppler time domain analysis of microembolic signals discriminate between gaseous and solid microemboli in patients with left ventricular assist device? *Neurol Res* 2005;27:780-4.
 60. Srinivasan J, Newell DW, Sturzenegger M, et al. Transcranial Doppler in the evaluation of internal carotid artery dissection. *Stroke* 1996;27:1226-30.
 61. Specker C, Rademacher J, Söhngen D, et al. Cerebral microemboli in patients with antiphospholipid syndrome. *Lupus* 1997;6:638-44.
 62. Bladin CF, Bingham L, Grigg L, et al. Transcranial Doppler detection of microemboli during percutaneous transluminal coronary angioplasty. *Stroke* 1998;29:2367-70.
 63. Nadareishvili ZG, Choudary Z, Joyner C, et al. Cerebral microembolism in acute myocardial infarction. *Stroke* 1999;30:2679-82.
 64. Kron J, Hamper UM, Petri M. Prevalence of cerebral microemboli in systemic lupus erythematosus: transcranial Doppler. *J Rheumatol* 2001;28:2222-5.
 65. Weber CA, Matzdorff AC, Gerriets T, Villmow T, Stolz E. Circulating microemboli in patients with myeloproliferative disorders. *Eur J Neurol* 2007;14:199-205.
 66. Kosmorsky G, Straga J, Knight C, et al. The role of transcranial Doppler in nonarteritic ischemic optic neuropathy. *Am J Ophthalmol* 1998;126:288-90.
 67. Moazami N, Roberts K, Argenziano M, et al. Asymptomatic microembolism in patients with long-term ventricular assist support. *ASAIO J* 1997;43:177-80.
 68. Yeh HH, Yang CC, Tung WF, et al. Young stroke, cardiac myxoma, and multiple emboli: a case report and literature review. *Acta Neurol Taiwan*. 2006;15:201-5.
 69. de Almeida LA, Hueb JC, de Moraes Silva MA, et al. Cerebral ischemia as initial neurological manifestation of atrial myxoma: case report. *Arq Neuropsiquiatr* 2006;64:660-3.